ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics


ClearPoint Neuro, Inc. (CLPT): $10.36

0.13 (+1.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLPT POWR Grades

  • Sentiment is the dimension where CLPT ranks best; there it ranks ahead of 90.13% of US stocks.
  • The strongest trend for CLPT is in Growth, which has been heading up over the past 177 days.
  • CLPT ranks lowest in Momentum; there it ranks in the 10th percentile.

CLPT Stock Summary

  • CLPT's price/sales ratio is 12.6; that's higher than the P/S ratio of 91.58% of US stocks.
  • With a year-over-year growth in debt of -40.17%, CLEARPOINT NEURO INC's debt growth rate surpasses merely 7.87% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, CLEARPOINT NEURO INC is reporting a growth rate of 89.33%; that's higher than 83.7% of US stocks.
  • If you're looking for stocks that are quantitatively similar to CLEARPOINT NEURO INC, a group of peers worth examining would be IDN, NSPR, SONO, KLTR, and TMDX.
  • CLPT's SEC filings can be seen here. And to visit CLEARPOINT NEURO INC's official web site, go to www.clearpointneuro.com.

CLPT Valuation Summary

  • In comparison to the median Healthcare stock, CLPT's price/sales ratio is 192.47% higher, now standing at 13.6.
  • CLPT's EV/EBIT ratio has moved down 9.7 over the prior 126 months.

Below are key valuation metrics over time for CLPT.

Stock Date P/S P/B P/E EV/EBIT
CLPT 2022-09-23 13.6 6.1 -15.9 -15.7
CLPT 2022-09-22 13.0 5.8 -15.1 -14.9
CLPT 2022-09-21 13.6 6.1 -15.8 -15.7
CLPT 2022-09-20 14.4 6.4 -16.7 -16.6
CLPT 2022-09-19 14.7 6.6 -17.1 -17.1
CLPT 2022-09-16 14.8 6.6 -17.2 -17.2

CLPT Growth Metrics

    Its 4 year price growth rate is now at -31.09%.
  • The year over year revenue growth rate now stands at 25.88%.
  • Its 3 year price growth rate is now at 111.64%.
CLPT's revenue has moved up $8,804,096 over the prior 33 months.

The table below shows CLPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 19.087 -16.098 -16.391
2022-03-31 17.3 -14.835 -15.831
2021-12-31 16.299 -12.697 -14.41
2021-09-30 15.73344 -11.547 -11.8429
2021-06-30 14.67863 -9.617486 -9.347127
2021-03-31 13.74341 -7.607604 -7.265175

CLPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLPT has a Quality Grade of C, ranking ahead of 36.69% of graded US stocks.
  • CLPT's asset turnover comes in at 0.297 -- ranking 130th of 186 Medical Equipment stocks.
  • ANGO, IVC, and MLSS are the stocks whose asset turnover ratios are most correlated with CLPT.

The table below shows CLPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.297 0.680 -0.308
2021-03-31 0.370 0.694 -0.245
2020-12-31 0.524 0.711 -0.240
2020-09-30 0.613 0.740 -0.337
2020-06-30 0.652 0.704 -0.416
2020-03-31 0.763 0.674 -0.596

CLPT Price Target

For more insight on analysts targets of CLPT, see our CLPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.00 Average Broker Recommendation 1.5 (Moderate Buy)

CLPT Stock Price Chart Interactive Chart >

Price chart for CLPT

CLPT Price/Volume Stats

Current price $10.36 52-week high $20.55
Prev. close $10.23 52-week low $7.00
Day low $10.18 Volume 66,600
Day high $11.11 Avg. volume 198,204
50-day MA $13.13 Dividend yield N/A
200-day MA $10.90 Market Cap 253.70M

ClearPoint Neuro, Inc. (CLPT) Company Bio


ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.


CLPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLPT Latest Social Stream


Loading social stream, please wait...

View Full CLPT Social Stream

Latest CLPT News From Around the Web

Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

The ClearPoint Prism™ Neuro Laser Therapy System The ClearPoint Prism™ Neuro Laser Therapy System SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), has received 510(k) clearance for its laser which the Company plans to commercialize as the ClearPoint Prism™ Neuro Laser The

Yahoo | September 23, 2022

ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

Mazin Sabra Mazin Sabra SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro’s Chief Executive Officer, and serve as a member of the Company’s senior leadership team. “We are thril

Yahoo | September 20, 2022

ClearPoint Neuro Announces FDA Clearance for Software Version 2.1

ClearPoint Neuro Navigation Software Version 2.1 ClearPoint Neuro Navigation Software Version 2.1 SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has obtained 510(k) clearance for version 2.1 of the ClearPoint Neuro Navigation software. Version 2.1 of the ClearPoint System is intended to provide stereotactic guidance fo

Yahoo | September 19, 2022

B.Riley Financial Sticks to Its Buy Rating for ClearPoint Neuro (CLPT)

In a report released today, Marc Wiesenberger from B.Riley Financial reiterated a Buy rating on ClearPoint Neuro (CLPT - Research Report), with a price target of $18.50. The company's shares opened today at $15.60.According to TipRanks, Wiesenberger is a 5-star analyst with an average return of 17.7% and a 48.32% success rate.Currently, the analyst consensus on ClearPoint Neuro is a Moderate Buy with an average price target of $18.50.See the top stocks recommended by analysts >>Based on ClearPoint Neuro's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.03 million and a GAAP net loss of $3.96 million.

Austin Angelo on TipRanks | August 10, 2022

ClearPoint Neuro Reports Second Quarter 2022 Results

Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue ForecastSOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2022. Second Quarter Highlights Reported record quarterly revenue of $5.2 million, a 52% year-over-year increase;Partner PTC Therapeutics received a pos

Yahoo | August 9, 2022

Read More 'CLPT' Stories Here

CLPT Price Returns

1-mo -16.99%
3-mo -17.19%
6-mo -8.16%
1-year -42.09%
3-year 139.81%
5-year 300.00%
YTD -7.66%
2021 -29.39%
2020 231.04%
2019 205.73%
2018 -42.91%
2017 -19.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5256 seconds.